🇺🇸 FDA
Patent

US 12203098

Cells having solid tumor targeting backbone and use thereof

granted A61KA61K39/39558A61K40/11

Quick answer

US patent 12203098 (Cells having solid tumor targeting backbone and use thereof) held by Fate Therapeutics, Inc. expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K39/39558, A61K40/11, A61K40/31, A61K40/4202